Pictet Biotech

Investing in the Pictet Biotech fund could be attractive considering the tremendous growth potential of the biotechnology industry but investors should be prepared to suffer high volatility.

Fernando Luque 3 December, 2003 | 6:25PM
Facebook Twitter LinkedIn
So far this year the Pictet Biotech fund has done well, rising over 40%, but other biotech funds sold across Europe have risen by over 60%.

Part of this relative underperformance is because of the fund’s underweight position in smaller companies, a segment of the market that has performed strongly this year. The fund invests about 33% in smaller firms compared with 37% for the average biotech fund.

Despite this underweight position in small firms, the size of the companies the fund holds is generally smaller than average. The median market capitalisation of its holdings is about $2 billion (£1.2 billion) compared with a median

of just over $3 billion for the biotech funds in Morningstar’s Life Science category.

This size tilt is consistent with the manager’s view of the sector. Michael Sjöstrom says medium-sized firms continue to show the best returns relative to risk. Yet that does not mean that the fund avoids industry leaders such as Amgen, Celgene or Gilead Sciences which are three of the biggest holdings in the portfolio. It also invests in some selective smaller companies.

Over the long term Pictet Biotech is one of the top performing biotech funds. From October 2000 through October 2003 it fell a cumulative 45% but over five years has risen by 127%. The average biotech fund fell by 53% and rose by 80% over the same periods.

Yet for investors it is probably more important to look at the fund’s risks. For example, the strong performance in the last five years hides the fact that the fund gained 65% and 83% respectively in 1999 and 2000 before losing about half of its value in 2002. This volatility is nevertheless in line with other biotech funds.

The fund is risky not only because biotechnology is a volatile sector but also because its portfolio is more concentrated than the average biotech fund. The top ten holdings represent 55% of its portfolio while the total number of holdings is also below average.

However, it would be wrong to judge this fund only by its two-star rating as within the category there is no pure biotech fund with more than two stars. The poor rating is largely a result of the fund’s high volatility and the tremendous decline in the sector over the last three years. From October 2000 to October 2003 the average biotech fund fell by over 50%.

[This article was amended on December 8th 2003].

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Pictet-Biotech P USD856.12 USD-0.07Rating

About Author

Fernando Luque

Fernando Luque  is Senior Financial Editor at Morningstar Spain 

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures